TASK DEFINITION: In this task, you're given a paragraph from the research paper and your task is to generate a suitable title for the research paper based on the given paper. Under 100 words is a good title length.
PROBLEM: Purpose: COVID-19 has become global threaten. CT acts as an important method of 60 diagnosis. However, human-based interpretation of CT imaging is time consuming. 61 More than that, substantial inter-observer-variation cannot be ignored. We aim at 62 developing a diagnostic tool for artificial intelligence (AI)-based classification of CT 63 images for recognizing COVID-19 and other common infectious diseases of the lung. 64 Experimental Design: In this study, images were retrospectively collected and 65 prospectively analyzed using machine learning. CT scan images of the lung that show 66 or do not show COVID-19 were used to train and validate a classification framework 67 based on convolutional neural network. Five conditions including COVID-19 68 pneumonia, non-COVID-19 viral pneumonia, bacterial pneumonia, pulmonary 69 tuberculosis, and normal lung were evaluated. Training and validation set of images 70 were collected from Wuhan Jin Yin-Tan Hospital whereas test set of images were 71 collected from Zhongshan Hospital Xiamen University and the fifth Hospital of 72 Wuhan. 73 Results: Accuracy, sensitivity, and specificity of the AI framework were reported. For 74 test dataset, accuracies for recognizing normal lung, COVID-19 pneumonia, 75 non-COVID-19 viral pneumonia, bacterial pneumonia, and pulmonary tuberculosis 76 were 99.4%, 98.8%, 98.5%, 98.3%, and 98.6%, respectively. For the test dataset, 77 accuracy, sensitivity, specificity, PPV, and NPV of recognizing COVID-19 were 78 98.8%, 98.2%, 98.9%, 94.5%, and 99.7%, respectively. 79 All rights reserved. No reuse allowed without permission. the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

SOLUTION: Deep Learning-Based Recognizing COVID-19 Deep Learning-Based Recognizing COVID-19 and other Common Infectious Diseases of the Lung by Chest CT 2 Scan Images

PROBLEM: Dendritic cells (DCs) are recognized as highly potent antigen-presenting cells that are able to stimulate cytotoxic T lymphocyte (CTL) responses with antitumor activity. Consequently, DCs have been explored as cellular vaccines in cancer immunotherapy. To that end, DCs are modified with tumor antigens to enable presentation of antigen-derived peptides to CTLs. In this review we discuss the use of viral vectors for in situ modification of DCs, focusing on their clinical applications as anticancer vaccines. Among the viral vectors discussed are those derived from viruses belonging to the families of the Poxviridae, Adenoviridae, Retroviridae, Togaviridae, Paramyxoviridae, and Rhabdoviridae. We will further shed light on how the combination of viral vector-based vaccination with T-cell supporting strategies will bring this strategy to the next level. Since their discovery in 1973, it was clear that dendritic cells (DCs) stood out above the immune cell pack (1, 2). They are morphologically distinct from all other immune cell types and are gifted with an unparalleled capacity to take up, process and present self and foreign antigens to both CD4 + and CD8 + T cells. DCs are critical intermediaries between the innate and adaptive immune systems, as they stimulate, regulate, and shape both immunity and tolerance in all its disguises. Ralph Steinmann, who discovered these cells, was awarded the Nobel Prize for Medicine in 2011, because the discovery of DCs changed medicine (3). Dendritic cells in both humans and mice represent a population of at least four different subtypes with distinct phenotypical and functional characteristics (4-7). These subsets are: plasmacytoid DCs (pDCs), two subsets of conventional DCs (cDC1 and cDC2), and inflammatory DCs. The latter represent a monocyte-derived subset that appears during inflammatory responses (Table 1) . Recently, additional types of human blood DCs, monocytes, and progenitors were revealed using single cell RNA-sequencing. The group of Prof. Nir Hacohen identified pDCs next to cDC progenitor-derived cDC1 (Clec9A + ) and two types of CD1c + cDC2, of which one can also be derived from CD14 + DCs. Furthermore they found a CD141 CD1c CD11c + DC subset derived from CD16 + monocytes and an AXL + Siglec6 + subset (8). Future research will have to unravel a possible murine representative for the human cDC2 and AXL + Siglec6 + DC subset. Also, Langerhans cells have been considered an important DC subset for vaccination as they are localized in the epidermis (HLA-DR + CD11c + CD1a + CD207 + ). However, recent evidence suggests that they are related to macrophages, another antigen-presenting cell (APC) type with potential antitumor activity (9).

SOLUTION: The Journey of in vivo Virus Engineered Dendritic Cells From Bench to Bedside: A Bumpy Road

PROBLEM: Most virus infections induce cycloxygenase-2 (COX-2) expression and subsequent prostaglandin E 2 (PGE 2 ) production in cells, an inflammatory response that might be detrimental to virus replication and pathogenesis. This response in dengue virus infection remains to be elucidated. Triptolide and tetrandrine, compounds derived from two commonly used Chinese herbs, both demonstrate anti-inflammatory and immunosuppressive effects partly through modulation of COX-2 expression and, hence, may have antiviral effects. In this study, we examined, firstly, the immune response to dengue virus infection with respect to COX-2 expression and PGE 2 production in human lung cells (A549), liver cells (HepG2) and dendritic cells. Secondly, we assessed the potential antiviral effects of triptolide and tetrandrine on dengue virus infection vis-a-vis expression of COX-2, PGE 2 , transcription factors, as well as virus production. We found that dengue virus infection enhanced COX-2 expression and PGE 2 production in A549 cells, similarly to the response in dendritic cells, but not in HepG2 cells. In dengue virus-infected A549 cells, nuclear factor B (NF-B) and activator protein 1 (AP-1) were also activated, and both were dose-dependently inhibited by triptolide (0.5-4 ng/ml). Tetrandrine (1-10 M) had no similar immunosuppressive effects and, moreover, at higher concentrations, enhanced NF-B and AP-1 activity, COX-2 expression and PGE 2 production. However, unexpectedly, tetrandrine, but not triptolide, dose-dependently suppressed dengue virus production in A549 cells, independent of PGE 2 level. Our findings imply that triptolide and tetrandrine may attenuate dengue virus infection in human lung cells, but through distinct pathways.

SOLUTION:
Differential effects of triptolide and tetrandrine on activation of COX-2, NF-B, and AP-1 and virus production in dengue virus-infected human lung cells